Personalized Stem Cells, Inc.

Executive Summary

Personalized Stem Cells, Inc. (PSC) is a San Diego-based biotechnology company offering FDA-compliant autologous mesenchymal stem cell (MSC) banking and processing services. The company isolates, expands, and cryopreserves MSCs derived from a patient's adipose tissue, enabling individuals to store their own cells as a biological asset for potential future regenerative therapies. PSC's model targets a growing market of proactive health management, primarily for orthopedic and degenerative conditions, and provides a personalized approach distinct from allogeneic stem cell treatments. By focusing on quality-controlled processing and long-term storage, PSC positions itself as a service provider rather than a drug developer, reducing regulatory hurdles while addressing the increasing demand for personalized regenerative medicine. Despite the promising concept, PSC faces challenges including limited clinical validation of stored MSCs' efficacy, competition from other stem cell banks and point-of-care therapies, and reliance on out-of-pocket payment models as insurance coverage for such services remains minimal. The company's success hinges on building consumer trust, establishing clinical evidence through partnerships, and scaling operations. With a lean business model and no reported revenue or funding rounds, PSC's near-term viability may depend on customer acquisition and strategic collaborations. The regenerative medicine market is expanding, but PSC must differentiate itself and demonstrate tangible value to patients and providers to achieve sustainable growth.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with orthopedic clinic network for cell banking referral program40% success
• Q4 2026Publication of long-term viability and quality data from stored MSC batches30% success
• TBDFDA clearance of expanded indication for autologous MSC use in osteoarthritis15% success